Skip Ribbon Commands
Skip to main content

NRAS Mutation Analysis Test




​This test complements the KRAS/BRAF Mutation Analysis Test and is indicated in the setting of metastatic colorectal cancer whereby the first round of screening for mutations in KRAS oncogene exons 2, 3 and 4 is already negative, i.e. to look for specific mutations in exons 2, 3 and 4 of the NRAS gene. The presence of certain NRAS mutations correlates with a lack of response to certain EGFR inhibitor cancer therapies in metastatic colorectal cancer patients.

Specimen Required

​Paraffin embedded tissue block sent to the Histopathology Section.

Alternatively, unstained slides can be sent to the Histopathology Section. At least 8 sections of 8 µm thickness, or 12 sections of 5 µm thickness for smaller biopsies should be sent together with one H&E slide, 4 µm thick with a coverslip as a reference slide. Tumour content must be indicated and must be at least 30%.

Storage and Transport


​Direct PCR sequencing (In-house test)

Test Results

​Specific mutations detected, No mutations Detected or Inconclusive

Reference Interval / Value

Turnaround Time

​5-10 days

Day(s) Test Set up



Change History Notes



What's New

Sort by :